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Purpose: There is a critical need for improvements in the noninva-
sive diagnosis of lung cancer. We hypothesized that matrix-assisted
laser desorption ionization mass spectrometry (MALDI MS) analy-
sis of the most abundant peptides in the serum may distinguish lung
cancer cases from matched controls.
Patients and Methods: We used MALDI MS to analyze unfrac-
tionated serum from a total of 288 cases and matched controls split
into training (n  182) and test sets (n  106). We used a
training–testing paradigm with application of the model profile
defined in a training set to a blinded test cohort.
Results: Reproducibility and lack of analytical bias was confirmed
in quality-control studies. A serum proteomic signature of seven
features in the training set reached an overall accuracy of 78%, a
sensitivity of 67.4%, and a specificity of 88.9%. In the blinded test
set, this signature reached an overall accuracy of 72.6 %, a sensi-
tivity of 58%, and a specificity of 85.7%. The serum signature was
associated with the diagnosis of lung cancer independently of
gender, smoking status, smoking pack-years, and C-reactive protein
levels. From this signature, we identified three discriminatory features
as members of a cluster of truncated forms of serum amyloid A.
Conclusions: We found a serum proteomic profile that discrimi-
nates lung cancer from matched controls. Proteomic analysis of
unfractionated serum may have a role in the noninvasive diagnosis
of lung cancer and will require methodological refinements and
prospective validation to achieve clinical utility.
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Lung cancer is the third most common cancer in the UnitedStates, but it is the leading cause of cancer-related deaths
in both sexes.1 The reference (“gold”) standard in diagnosing
lung cancer is pathological evidence of malignant cells,
which typically requires an invasive strategy such as bron-
choscopy, transthoracic needle aspiration, or even surgery.
New, noninvasive approaches are urgently needed to improve
our diagnostic accuracy and to avoid futile thoracotomies and
missed chances of taking patients to surgery early when
needed. Although various serum biomarkers have been in-
vestigated in lung cancer diagnosis, none has proven useful in
general clinical practice, primarily because of limited sensi-
tivity and specificity. Among the most extensively investi-
gated biomarkers, the literature is very heterogeneous, and
most biomarkers lack validation in large, prospective studies.
The sensitivity of carcinoembryonic antigen in the diagnosis
of lung cancer ranges from 26% to 33% when the specificity
is set at the 95% level.2–4 For squamous cell carcinoma
antigen, the sensitivity ranges between 39% and 41% when
specificity is set at 95%.2,3 The sensitivity of cytokeratin 19
fragment ranges between 36% and 81% with a specificity set
at 95%.2–4 Finally, for neuron-specific enolase, the sensitivity
ranges between 18% and 39% with a specificity set at 95%.2,4
Thus, their use for diagnosis has not had a significant impact
on patient care.
With recent advances in mass spectrometry techniques,
it is now possible to investigate protein expression profiles
from biological specimens, in health and disease, over a wide
range of molecular weights.5,6 We and others have recently
demonstrated that proteomic profiling of lung tumors using
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matrix-assisted laser desorption ionization mass spectrometry
(MALDI MS) or two-dimensional gel electrophoresis meth-
ods allows distinction between normal and cancer tissue, and
may predict lymph node involvement or survival.7,8 Recent
studies have reported serum protein expression profiles that
distinguish cancer patients diagnosis and outcomes with a
variety of malignancies from controls using MALDI-based
approaches.9–14 Questions about analytical reproducibility
and validation have led to some controversy about this and
other “-omics” discovery approaches.15–20
The goal of this study was to identify a proteomic
signature directly obtained from unfractionated serum to
distinguish lung cancer cases from matched controls with an
easy, rapid technology such as MALDI MS. Careful attention
has been directed to those critical issues of reproducibility
and variability (both analytical and biological) in a large
number of samples from two institutions. A serum protein
signature consisting of seven peptides is found to be associ-
ated with lung cancer, which was tested in a blinded test set
of matched samples.
PATIENTS AND METHODS
Study Subjects
Sera from a total of 142 patients with lung cancer
(cases) and 146 individuals with no evidence of cancer were
included in this matched case–control study (Tables 1 and 2).
Cases were included with pathologically proven lung can-
cer of common subtypes and at all stages. The cases did
not have therapeutic intervention for lung cancer within
the 3 months preceding the blood draw. One hundred
twenty-four patients carrying a diagnosis of chronic ob-
structive pulmonary disease, 28 with asthma, 59 with
coronary artery disease, 30 with diabetes mellitus, and 53
with hypercholesterolemia were included and were evenly
distributed between cases and controls (see Supplemental
Table 1). Sera were collected prospectively from Vander-
bilt University Medical Center Clinics, the Nashville VA
Medical Center clinics, and the University of Pittsburgh
Cancer Institute Lung Cancer SPORE Lung CT Screening
Study between Jan 2001 and Aug 2003 (see Supplemental
Table 2).
Study Design
The case–control study design is summarized in Figure
1. The cases and controls were matched to avoid confounding
variables such as age, sex, and particularly smoking history to
explain the difference between groups. The matched cases
and controls were split into a training (n  182) and a test set
(n  106). A model signature defined in a training set was
tested in the test set of matched cases and controls. Cases
were individually matched with controls according to sex,
age, smoking status, and total pack-year history. Two thirds
of the serum paired samples were assigned to a training set,
and the remaining third of the samples were assigned to a
validation test set. Training and test sets were matched
according to the same criteria and balanced for histology,
stage, and nodal status (Tables 1 and 2). Forty control
samples from the University of Pittsburgh were distributed
equally between training and test sets. The institutional re-
view boards of Vanderbilt University and the University of
Pittsburgh approved this study.
To determine whether our signature was associated
with the diagnosis of lung cancer independently of an inflam-
matory response, the association between the signature and
C-reactive protein (CRP) levels (high-sensitivity CRP, Alfa
Wassermann, West Caldwell, NJ)21 in 223 of 288 serum
samples was examined using the multivariable model of
analysis described below.
Sample Preparation, MALDI MS Spectrum
Acquisition, and Data Processing
Peripheral blood was collected without additive, incu-
bated at room temperature for 60 minutes, and centrifuged.
Serum was aliquoted and stored within 4 hours at 80° C
until analysis. Thawed serum samples were diluted 1:10 in
TABLE 1. Clinical Characteristics of the 288 Lung Cancer Cases and Matched
Controls in the Training and Test Sets
Training Set (182) Matched Test Set (106)
Cases Controls Cases Controls
Individuals, no. 92 90 50 56
Sex, no. (%)
Male 61 (66) 60 (67) 30 (60) 29 (52)
Female 31 (34) 30 (33) 20 (40) 27 (48)
Age (yr), mean  SD 63.7 (9.7) 61.2 (7.1) 63.6 (12.0) 60.9 (9.2)
Smoking status, no. (%)
Ex 48 (52) 48 (53) 25 (50) 25 (45)
Current 41 (45) 39 (43) 20 (40) 27 (48)
Never 3 (3) 3 (5) 5 (10) 4 (7)
Smoking (pack-years),
mean  SD
58.6 (34.5) 68.2 (40.1) 49.1 (26.6) 60.8 (23.6)
PKY, pack-years (product of the number of packs of cigarettes smoked per day and the number of years of
smoking).
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water. One microliter of matrix solution (sinapinic acid in
acetonitrile/water 50:50 v/v containing 0.1% trifluoroacetic
acid) was mixed with one microliter of diluted serum and
directly spotted in duplicate onto a gold-coated stainless steel
MALDI target plate (PE Biosystems, Foster City, CA). Spec-
tra were acquired with a Voyager-Elite MALDI mass spec-
trometer (Applied Biosystems, Foster City, CA). Spectra
were generated in the mass to charge (m/z) 3,000 to 20,000.
Internal calibration was performed using the hemoglobin 
chain ([MH] 15868) and APO-C1 ([MH] 6631).
The data preprocessing consisted of internal calibration,
smoothing, baseline correction, normalization to the total ion
current, feature selection with a signal-to-noise ratio, and
binning of features (see Supplemental Data 1a). The process-
ing resulted in 120 m/z peaks per spectrum on average. A
total of 162 bins from m/z ratios of 3,000 to 20,000 were
selected. In addition, 75 bins reached S/N 3, from which
five peaks related to hemoglobin were removed from the
analysis. The 70 remaining peaks were used for statistical
analysis. Data acquisition and processing are summarized in
Figure 2.
Multidimensional LC/MS/MS Analyses and
Protein Identification
Proteins from case and control samples were sepa-
rated by one-dimensional gel electrophoresis. Bands were
excised in the molecular weight range of 11,000 to 12,000
Da, corresponding to a subset of m/z of discriminatory
peaks. Bands were in-gel tryptic digested, and subjected to
LC/MS/MS analysis on a Thermo LTQ linear ion trap
instrument equipped with a thermonanoelectrospray source,
TABLE 2. Patient’s Clinical Characteristics in the Training
and Test Lung Cancer Case Sets
Training Cases
(92), n (%)
Matched Test Cases
(50), n (%)
Stage NSCLC
I 24 (26.1) 14 (28)
II 8 (8.7) 4 (8)
III 29 (31.5) 12 (24)
IV 22 (23.9) 15 (30)
Stage SCLC
Limited 4 (4.3) 2 (4)
Extensive 5 (5.4) 3 (6)
Histology
Squamous 34 (37) 16 (32)
Adenocarinoma 33 (35.9) 21 (42)
Large 5 (5.4) 2 (4)
NSCLC 9 (9.8) 5 (10)
Small cell 9 (9.8) 5 (10)
Other 2 (2.2) 1 (2)
Nodal Status
N0 34 (37) 18 (36)
N1 6 (6.5) 5 (10)
N2 27 (29.3) 14 (28)
N3 10 (10.9) 6 (12)
Unknown 15 (16.3) 7 (14.0)
NSCLC, non-small cell lung cancer; SCLC, small-cell lung cancer; n, number of
individuals.
FIGURE 1. Flowchart describing the study design. A set of
matched cases and controls (n  288) was split into a train-
ing set (n  182) and a test set (n  106). A model signa-
ture defined in a training set was tested in a test set of
matched cases and controls.
FIGURE 2. Workflow of serum profiling by MALDI MS ac-
quisition and data processing. One-microliter samples were
diluted 1:10 in water before printing to a MALDI plate. One
microliter of 10 mg/ml 3,5-dimethoxy-4-hydroxy-cinnamic
acid in 50:50 acetonitrile/0.1% trifluoroacetic acid was
placed on the surface and allowed to dry. MALDI-MS spectra
were acquired using a PerSeptive Voyage Elite time-of-flight
mass spectrometer equipped with delayed extraction and a
nitrogen laser (337 nm). All spectra were acquired in the
linear mode with delayed extraction, using a laser intensity
of 2300 (arbitrary units). Signal-to-noise (S/N) calculations
included both chemical and electronic noise. Data were then
processed for calibration, smoothing, baseline correction,
normalization, feature selection by S/N ratio, binning, align-
ment, and normalization. Data were analyzed, and discrimi-
natory signatures were obtained after statistical tests for class
comparison. Discriminatory features were selected after sta-
tistical threshold and visual confirmation of the nature of the
peak. Prediction of diagnostic accuracy was provided by the
weighted flexible compound covariate method. Signature
was validated in two independent sets of spectra. A sub-
group of masses was identified by gel electrophoresis, fol-
lowed by protein digestion and tandem MS–MS.
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Surveyor LC system, and autosampler (Thermo Fisher, San
Jose, CA). Tandem MS spectra were matched to the human
database sequences using SEQUEST (Thermo Fisher, San
Jose, CA). SEQUEST results were filtered according to
stringent charge and cross-correlation scores (XCorr) and
RSp (ranking of primary score) value of 5 and Sp value
(primary score) 350. SEQUEST-identified peptide se-
quences, protein accession numbers, and target MALDI MS
m/z values were entered into FRAGMINT, a new software
utility that generated candidate protein fragments consistent
with the identified protein and peptide sequences and the
observed MALDI MS m/z values.22
Statistical Analysis
The statistical analyses for the primary objective were
focused on the following steps: (a) selection of MS features
and differential expression levels between the study groups
(for details, see Supplemental Data 2); (b) on the basis of the
selected features, a class-prediction model7,23–26 was applied
to determine whether the proteomic patterns could classify
cases from controls. The misclassification rate was estimated
using the leave-one-out cross-validation. (c) The prediction
model generated from the training set was applied to the
blinded test set. Receiver operating characteristic curves
based on the weighted flexible compound covariate method
models were also evaluated. Detailed statistical methods are
provided in Supplemental Data 2. The accuracy rate was also
estimated using the support vector machine (SVM) method
with the polynomial kernel of degree 3.27 The SVM performs
classification by constructing an n-dimensional hyperplane
that optimally separates the data into two categories: cases
versus controls. SVM models are closely related to neural
networks and are widely used in high-dimensional data anal-
ysis. In addition, to assess the consistency of the analysis of
the data, the entire raw dataset (288 spectra) was indepen-
dently processed and analyzed by a collaborator (HR) at an
outside institution. Finally, the multivariate logistic regres-
sion model was applied to study the association between
serum profile and the diagnosis of lung cancer, adjusted for
age, gender, pack-years of smoking, and CRP levels.
RESULTS
Reproducibility and Variability
The reproducibility and variability (both analytical and
biological) were first tested in a total of 312 spectra from a
total of 18 serum samples. We first analyzed the variance
between all m/z peak intensities after calibration, smoothing,
alignment, and normalization from the same sample. Quadru-
plicate MS spectra of the same spots were obtained, and each
sample was analyzed four times on different spots. Reported
are coefficients of variation (CV) for four spectra obtained
from the same spot across four separate samples (same spot,
CV  1.43%), and variability of four separate samples (spot
to spot, CV  1.15%) (Table 3). The variability of spectra
TABLE 3. Reproducibility and Variability of Matrix-Assisted Laser Desorption Ionization Mass
Spectrometry Approach to Unfractionated Serum
Analytical Variability
Average CV (%)
for All Masses to
Charge
No. of
Spectra
Average CV (%)
for Specific
Masses to Charge
No. of Spectra
Testing Set
Same spot 1.43 64
Spot to spot 1.15 64
Freeze-and-thaw cycles (overall) 6.24 64
1 7.9 16
2 3.09 16
3 1.76 16
4 12.21 16
Day to day (overall) 3.53 256
Day 1 5.46 16
Day 2 2.38 16
Day 3 4 16
Day 4 2.27 16
Masses to charge of classifiers
4155 5.28 182 5.37 106
7616 4.77 182 5.68 106
8765 5.27 182 5.04 106
11440 9.70 182 7.87 106
11526 11.43 182 9.60 106
11683 12.96 182 11.52 106
13762 5.42 182 4.44 106
Average CV assesses variance using all m/z peaks and corresponds to averages using coefficients of variation from quadruplicates. For
m/z of classifiers, average CV assesses variance using a given peak and corresponds to averages over samples using coefficients of variation
from the duplicates.
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acquired from the same serum spotted on four different days
(day to day) and before and after four cycles of freezing and
thawing was examined, and overall CVs of 6.24% and 1.76%
to 12.21%, respectively, were obtained. To quantify the
reproducibility of MALDI MS spectra measurement, the
intraclass correlation coefficient among 18 samples processed
in quadruplicate was determined. The average intraclass vari-
ability was 32%, and the intersample variability was 68%. CVs
for candidate biomarkers across training and test sets are shown
in Table 3, with no significant differences found between the
groups. In addition, we did not find significant difference in the
CVs for each of the seven classifiers between controls from
either institution. Hierarchical clustering analysis also demon-
strated that the profiles did not cluster according to days of
operation or institution of origin (data not shown).
Serum Proteomic Profile Diagnostic
Performance in Training and Test Sets
From the preprocessing, 75 of 162 peaks with signal-
to-noise ratios 3 were selected. From the training set, 14
peaks were selected to reach the statistical criteria, using a
p 107 (and not according to the best fit of the model). Seven
of the 14 features most likely corresponded to Na or K
adducts or double-charged ions of other peptides already con-
sidered as discriminatory features; therefore, they were removed
from the list of features. Our prediction analysis was thus based
on a conservative selection of seven individual m/z values, listed
and presented graphically in Supplemental Data 4.
On the basis of these seven discriminatory features, we
correctly classified 62 of 92 cases and 80 of 90 controls in the
training set, yielding a sensitivity of 67.4%, a specificity of
88.9%, and an overall classification accuracy of 78%. We
applied this signature to the matched blinded test set, and we
correctly classified 29 of 50 cases and 48 of 56 controls
(sensitivity of 58% and specificity of 85.7%) (Table 4).
Misclassified serum samples were found among all histolog-
ical subgroups and pathological stages. Very similar results
are reported from our SVM analysis (Table 4). In addition,
totally independent analysis of our dataset reported similar
prediction rates and selection of classifiers (Supplemental
Data 3). Average intensities of MALDI MS serum spectra
from cases and matched controls are presented in Figure 3
and Supplemental Data 1b.
Receiver operating characteristic analysis illustrates the
efficacy of the serum proteomic profile in distinguishing
between cases and controls in the two datasets (182 training
sample set, 106 matched test set) and are shown in Figure 4A.
The clinical impact of a diagnostic signature for lung
cancer would be greatest if it were able to identify cases of
early-stage lung cancer. We therefore searched for a protein
signature discriminating stage I lung cancer from matched
controls. Despite the smaller sample size, we identified a set
of six MS signals that detected stage I lung cancer with
sensitivity and specificity of 70.8% and 84.4%, respectively,
in a training set, and 57.1% and 71.4% in the test set (see
Supplemental Table 3).
To assess the effect of serum proteomic profile on the
diagnosis of lung cancer, the multivariable logistic regression
model was applied on a total of 223 samples, including both
cases and controls. The serum proteomic profile was associ-
ated with the diagnosis of lung cancer after adjustment for
age, gender, pack-years of smoking, and CRP levels (p 
0.001). The serum proteomic profile has the strongest asso-
ciation with the diagnosis of lung cancer among all the
covariates in the model (Figure 4B). The odds of being
diagnosed of lung cancer increased with the strength of the
serum proteomic profile; the odds ratio of being diagnosed
with lung cancer are 4.7, when comparing serum proteomic
profile in the fourth quantile with those in the first quantile
(Figure 4C).
Protein Identification
Although not the primary goal of this report, three
features were identified with the highest discriminatory value.
Statistical rank, relative m/z peak intensity, and prevalence of
the discriminatory peak were used to select the features of
interest. We identified a cluster of peptides around 11,500 Da,
which are part of the signature distinguishing cases from
controls. After SDS-PAGE separation of serum proteins, the
11,500-Da region of the gel was excised, digested, and
analyzed using microcapillary LC/MS/MS followed by data
analysis. On the basis of the SEQUEST-identified peptides,
TABLE 4. Performance of Matrix-Assisted Laser Desorption Ionization
Mass Spectrometry Serum Signature (Seven Features) to Distinguish Cases
of Lung Cancer from Matched Controls After Two Methods of Analysis:
the Weighted Flexible Compound Covariate Method (WFCCM) and
Support Vector Machine (SVM)
Training Set Test Set
WFCCM SVM WFCCM SVM
Cases 92 92 50 50
Controls 90 90 56 56
Accuracy (95% CI) 78.0 (72, 84) 81.32 72.6 (64, 81) 79.25
Sensitivity (95% CI) 67.4 (58, 77) 70.00 58.0 (44, 72) 64.00
Specificity (95% CI) 88.9 (82, 95) 93.33 85.7 (77, 95) 92.86
Misclassified cases 30 28 21 18
Misclassified controls 10 6 8 4
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FRAGMINT generated three candidate truncated fragments
originating from serum amyloid A (SAA) at 11,440, 11,525,
and 11,682 Da (Figure 5A and B), which were consistent with
the molecular weights of the discriminatory m/z values. Both
peptides GPGGAWAAEVISDAR and GPGGVWAAEIS-
DAR were identified in the lung cancer serum signature,
allowing for both SAA protein precursor and serum amyloid
A1 isoform 2 to be considered as possible sources of these
discriminatory peaks in the MALDI MS spectra. These re-
sults were further confirmed by Western analysis on 10 cases
and control serum samples (Figure 5C) and by immunodeple-
tion showing that the SAA peaks disappeared (Figure 5D).
DISCUSSION
We report a protein signature consisting of seven fea-
tures obtained by MALDI MS directly from 1 l of unfrac-
FIGURE 3. MALDI MS serum
spectra from individuals with lung
cancer and matched controls. Av-
erage intensity of spectrum analy-
sis between matched cases (red
plain line) and controls (blue dotted
line) are presented. Arrows point
to m/z values of discriminatory
features.
FIGURE 4. (A) Receiver operating
characteristic curves addressing
diagnostic efficacy of cases and
controls in the two datasets (182
training sample set, 106 matched
test set). (B) Nonmonotonic (qua-
dratic in ranks) generalization of
the Spearman rank–correlation co-
efficient, for each of these five pre-
dictors. The generalized Spearman
coefficient helps to describe the
strength of marginal relationships
between each of these predictor
variables and the response (being
with lung cancer or not). This plot
shows that the serum profile has the
strongest correlation with the re-
sponse among these five predictors.
(C ) Odds ratio of being diagnosed
with lung cancer according to se-
rum profile quantile distribution.
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tionated serum that distinguishes patients with lung cancer
from matched controls with an overall 72.6% accuracy in a
blinded test set of matched cases and controls. This proteomic
signature classifies cases from matched controls, indepen-
dently of sex, smoking status, pack-years of smoking history,
or CRP levels. This suggests that this signature identifies
more than a nonspecific inflammatory response. In addition,
the specificity of this signature (85.7 %) may provide added
value to a sensitive test (such as chest computed tomography)
in reducing the risk of futile thoracotomies, and in avoiding
missing a chance of cure should the test be negative, a
hypothesis that deserves further investigation. These data
represent the largest set of serum samples of lung cancer
cases and carefully matched controls studied by MALDI MS
in an attempt to address noninvasive diagnosis of lung cancer.
The careful matching of cases and controls with significant
comorbidities such as chronic obstructive pulmonary disease,
asthma, and other comorbidities is likely to explain the lower
diagnostic accuracy reported earlier.13 Although requiring
confirmation in a larger dataset, we also found that a serum
proteomic signature acquired by MALDI MS may be appli-
cable to the diagnosis of stage I lung cancer (see Supplemen-
tal Table 2).
The data presented here demonstrate the necessity for
spectral reproducibility when applying a MALDI MS-based
analysis of serum. CVs reported are similar to those reported
FIGURE 5. (A) One-dimensional SDS-PAGE analysis of proteins from control and lung cancer serum samples. Serum proteins were
separated using SDS-PAGE on a 10% to 20% tricine gel and stained using colloidal blue. The gel illustrates a band in the molecular
weight range of 11 to 12 kDa that appears frequently in lung cancer samples but is absent in the controls. This region was excised
from control and cancer samples, trypsin digested, and subjected to LC-MS-MS analysis. Lane 1, molecular weight markers; lanes 2
through 4, control serum; lanes 5 through 7, lung cancer serum. (B) Proteins identified from these bands included several variants of
serum amyloid A (SAA) that were unique to the lung cancer samples. FRAGMINT generated candidate protein fragments from se-
rum amyloid A1 isoform 2, which contained the SEQUEST-identified peptides and were consistent with the observed MALDI MS
m/z values. Peptides identified are underlined. The peptides contained in the sequence from positions 43 to 105 were also identi-
fied but are not shown. The intact sequence for serum amyloid A1 isoform 2, with an intact m/z value of 13532, is presented be-
low the possible truncated forms. (C ) SAA protein expression assessed by Western blot analysis in 10 serum samples, five from pa-
tients with lung cancer (cases) and five from controls. (D) Immunodepletion of SAA removes the peaks at m/z of 11526 and 11682
from serum samples of patients with cancer. Twenty microliters of packed rec-protein G–sepharose 4B conjugate (Zymed Lab Inc.,
CA) were incubated for 2 hours with 40 g of mouse monoclonal antihuman SAA antibody (Antigenix America Inc., NY) or with
immunoglobulins (mouse IgG, Santa Cruz, CA). Antibody–protein G–sepharose complex was washed with phosphate-buffered sa-
line and incubated with 20 l of serum overnight at 40°C. The supernatant collected after brief centrifugation was considered as
SAA-depleted serum. One microliter each of the serum, the SAA-depleted serum, and the serum incubated with control immuno-
globulins were diluted 1:10 and subjected to MALDI MS analysis.
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by others.28–30 It is recognized that many factors other than
the underlying biology such as sample preparation, choice of
instrument, and patient selection31 may influence the results
through systematic biases. Although it is difficult to com-
pletely eliminate these factors, and despite the inherent het-
erogeneity in the samples under study, we specifically con-
trolled for and evaluated these factors in detail. On the basis
of our results, the variability observed between cases and
controls represents true biological variability and is unlikely
to be attributable to chance alone or to variability-related day
of operation, cycles of freezing and thawing, or institution of
origin. Overfitting is a possible limitation of the statistical
methods applied to our data; nevertheless, the results from the
training dataset are applied only once to the testing dataset,
which is a conservative method to avoid overinterpretation of
the results.
Our primary goal was not to discover causal or tumor-
derived lung cancer–specific biomarkers among the most
abundant serum proteins, but to determine the accuracy of a
serum proteomic signature in distinguishing lung cancer
cases from matched controls. Such a lung cancer–associated
signature could potentially have clinical value independently
of functional role of the proteins and peptides detected.
Specific peptide fragments of SAA were identified as three
discriminatory features of the profile. We confirmed the
identification of SAA by Western blot and immunodepletion
(Figure 5). Our results support, but do not prove, the concept
of biological amplification. According to this concept, the
systemic consequences of tumors detected by MALDI MS
profiling of relatively abundant peptides from the serum
produce patterns that distinguish health from disease
states,6,32,33 reflecting specific host–response reactions to tu-
mors. SAA is an acute phase reactant secreted into the
circulation in a series of inflammatory and malignant pro-
cesses,32,34 including lung cancer.35–38 SAA measured by
enzyme-linked immunosorbent assay in the serum of patients
with lung cancer and age- and gender-matched controls as a
single biomarker was found to have limited 52% to 62%
overall diagnostic accuracy.38 Our data support these findings
and demonstrate that when SAA and specific truncated
forms are combined with other biomarkers in a proteomic
signature, they improve the diagnostic accuracy of a serum
proteomic profile.
Limitations of the approach used in this study restricted
the analysis to relatively abundant peptides/proteins within a
mass range of 3,000 to 20,000, a small fraction of the serum
proteome. This is primarily attributable to ion-suppression
effects, dilution, lack of fractionation of the serum, and,
secondarily, to the reduced resolution and sensitivity of
MALDI MS technology at higher mass ranges.39 In addition,
high abundant proteins in the serum may obscure our ability
to detect lower-abundance proteins.40 Another limitation in-
herent is our case–control design, which, although efficient,
is susceptible to selection bias.41
From this study, we conclude that we found a serum
proteomic profile that discriminates lung cancer from
matched controls independently of smoking history and
markers of inflammation CRP. These results are explained by
biological variability between samples as opposed to chance
or analytical variability. To achieve clinical utility, and to
demonstrate a role in the noninvasive diagnosis of lung
cancer, this proteomic approach is likely to require further
methodological refinements for simplifying the proteome,
either by biochemical fractionation, enrichment of subpro-
teomes, immunodepletion of the most abundant proteins, or
further validation in prospectively collected samples, as well
as proof of added value to the existing noninvasive diagnostic
strategies.
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